Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
ASTRAZENECA PHARMA TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASTRAZENECA PHARMA Mar-23 |
TEVA PHARMA Dec-13 |
ASTRAZENECA PHARMA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 3,620 | 3,486 | - | |
Low | Rs | 2,438 | 3,028 | - | |
Sales per share (Unadj.) | Rs | 401.2 | 2,000.5 | - | |
Earnings per share (Unadj.) | Rs | 39.7 | 125.0 | - | |
Cash flow per share (Unadj.) | Rs | 46.2 | 286.7 | - | |
Dividends per share (Unadj.) | Rs | 16.00 | 109.40 | - | |
Avg Dividend yield | % | 0.5 | 3.4 | 15.7% | |
Book value per share (Unadj.) | Rs | 234.4 | 2,222.2 | - | |
Shares outstanding (eoy) | m | 25.00 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 7.5 | 1.6 | 463.7% | |
Avg P/E ratio | x | 76.3 | 26.1 | 292.6% | |
P/CF ratio (eoy) | x | 65.5 | 11.4 | 576.8% | |
Price / Book Value ratio | x | 12.9 | 1.5 | 881.4% | |
Dividend payout | % | 40.3 | 87.5 | 46.0% | |
Avg Mkt Cap | Rs m | 75,718 | 2,761,843 | 2.7% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 2,591 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,744.4 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,357.9 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 10,030 | 1,696,422 | 0.6% | |
Other income | Rs m | 261 | 0 | - | |
Total revenues | Rs m | 10,291 | 1,696,422 | 0.6% | |
Gross profit | Rs m | 1,249 | 464,566 | 0.3% | |
Depreciation | Rs m | 163 | 137,123 | 0.1% | |
Interest | Rs m | 6 | 33,320 | 0.0% | |
Profit before tax | Rs m | 1,341 | 294,122 | 0.5% | |
Minority Interest | Rs m | 0 | 1,336 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -193,075 | -0.0% | |
Tax | Rs m | 348 | -3,591 | -9.7% | |
Profit after tax | Rs m | 993 | 105,974 | 0.9% | |
Gross profit margin | % | 12.5 | 27.4 | 45.5% | |
Effective tax rate | % | 26.0 | -1.2 | -2,126.2% | |
Net profit margin | % | 9.9 | 6.2 | 158.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 9,359 | 1,145,757 | 0.8% | |
Current liabilities | Rs m | 4,844 | 999,197 | 0.5% | |
Net working cap to sales | % | 45.0 | 8.6 | 521.1% | |
Current ratio | x | 1.9 | 1.1 | 168.5% | |
Inventory Days | Days | 49 | 91 | 54.5% | |
Debtors Days | Days | 39 | 96 | 40.8% | |
Net fixed assets | Rs m | 2,061 | 554,089 | 0.4% | |
Share capital | Rs m | 50 | 4,176 | 1.2% | |
Net worth | Rs m | 5,861 | 1,884,403 | 0.3% | |
Long term debt | Rs m | 0 | 867,418 | 0.0% | |
Total assets | Rs m | 11,421 | 3,876,868 | 0.3% | |
Interest coverage | x | 213.9 | 9.8 | 2,176.2% | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 0.9 | 0.4 | 200.7% | |
Return on assets | % | 8.7 | 3.6 | 243.5% | |
Return on equity | % | 16.9 | 5.6 | 301.2% | |
Return on capital | % | 23.0 | 4.9 | 466.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 583 | 270,322 | 0.2% | |
From Investments | Rs m | 181 | -95,786 | -0.2% | |
From Financial Activity | Rs m | -245 | -324,269 | 0.1% | |
Net Cashflow | Rs m | 519 | -149,733 | -0.3% |
Compare ASTRAZENECA PHARMA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare ASTRAZENECA PHARMA With: ADVIK LABORS SUDARSHAN PHARMA PFIZER VIMTA LABS BACIL PHARMA
Asian share markets are mixed today after US shares extended their losing streak to the longest since January 2024.